Nothing Special   »   [go: up one dir, main page]

Chaudhari, 2024 - Google Patents

Investigations on the Potential Role of Tripartite Motif 34 (TRIM34) Expression in Lung Cancer Tumorigenesis

Chaudhari, 2024

Document ID
216154445513745439
Author
Chaudhari K
Publication year
Publication venue
PQDT-Global

External Links

Snippet

Cancer is a complex and multifaceted disease characterized by the uncontrolled growth and spread of abnormal cells in body. It is the second leading cause of death globally, demanding extensive scientific research for improved understanding and therapeutic …
Continue reading at search.proquest.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Cocco et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives
Zhang et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma
Ambrogio et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Tsvetkov et al. Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
Poon et al. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Yang et al. DNA-sensing and nuclease gene expressions as markers for colorectal cancer progression
Angulo et al. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments
US20180306796A1 (en) Methods and compositions relating to proteasome inhibitor resistance
WO2015089338A9 (en) Glucocorticoid inhibitors for treatment of prostate cancer
Liddiard et al. DNA Ligase 1 is an essential mediator of sister chromatid telomere fusions in G2 cell cycle phase
Elsayed et al. Back to the future: rethinking the great potential of lncRNAS for optimizing chemotherapeutic response in ovarian cancer
US20180353445A1 (en) Methods and compositions relating to proteasome inhibitor resistance
Schumann et al. Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner
Lee et al. Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer
Xiang et al. A Ubiquitin‐Dependent Switch on MEF2D Senses Pro‐Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer
Misek et al. Ibrutinib blocks YAP1 activation and reverses BRAF inhibitor resistance in melanoma cells
Danisik et al. Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology
Chaudhari et al. Investigations on the Potential Role of Tripartite Motif 34 (TRIM34) Gene Expression in Lung Cancer Tumorigenesis
Martins et al. A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress–Induced Inflammation
Bhin et al. MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
Meira et al. Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
Wu et al. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index
Deeg et al. Dissecting telomere maintenance mechanisms in pediatric glioblastoma
Awad et al. Integrated drug profiling and CRISPR screening identify BCR:: ABL1-independent vulnerabilities in chronic myeloid leukemia
Ge et al. A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation